Christianson Mark 4

What Happened

• Mark Christianson, Business Development Director at NEUROONE MEDICAL TECHNOLOGIES (NMTC), disposed of a total of 15,616 shares in two related transactions at the end of March 2026. He sold 15,363 shares in an open-market sale at $0.74 per share (proceeds $11,369) and 253 shares were disposed under an F-code (payment of exercise price or tax liability) at $0.78 per share (value $197). Overall proceeds/values from the reported dispositions total approximately $11,566. These were sales/withholdings (not purchases), which are often routine rather than a bullish signal.

Key Details

• Transaction dates and prices:
  • 2026-03-30: Open-market sale (Code S) — 15,363 shares at $0.74 each; proceeds $11,369.
  • 2026-03-31: Payment of exercise price/tax withholding (Code F) — 253 shares at $0.78 each; value $197.
• Total shares disposed: 15,616; total value ≈ $11,566.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: The F-code indicates shares were withheld/used to satisfy an exercise price or tax liability (common when options vest or awards are taxed).
• Timeliness: Form 4 filed 2026-04-01 for trades on 2026-03-30 and 2026-03-31; filing appears timely (no late-file indicator).

Context

• No purchase or exercise-for-cash behavior here—this filing documents an open-market sale and a small withholding of shares to cover taxes/exercise costs. The F-code withholding often follows an earlier option exercise or award vesting; this filing itself does not show a new option exercise event. No 10b5-1 plan or other trading-plan notation is indicated in the supplied details.